Molecular Subtypes of Non-Muscle-Invasive Bladder Cancer

TY - CHAP

T1 - Molecular Subtypes of Non-Muscle-Invasive Bladder Cancer

AU - Prip, Frederik

AU - Lindskrog, Sia Viborg

AU - Lamy, Philippe

AU - Strandgaard, Trine

AU - Nordentoft, Iver

AU - Birkenkamp-Demtröder, Karin

AU - Dyrskjøt, Lars

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2024.

PY - 2025/1

Y1 - 2025/1

N2 - Non-muscle-invasive bladder cancers (NMIBCs) show large variation in disease aggressiveness and treatment response which is not fully explained by differences in clinical and pathological factors. Researchers have therefore studied different molecular layers of tumors, mainly gene expression profiling, to unravel underlying molecular subtypes that can explain this phenotypic variation. In addition, molecular subtypes can potentially be used for risk stratification of patients and prediction of treatment response based on the biological tumor features. NMIBC subtypes have been investigated in combination with muscle-invasive bladder cancers (MIBCs), using NMIBCs only and separated by tumor stage. Molecularly high-risk tumors across schemes are generally characterized by pronounced cell cycle activity, frequent TP53 alterations and a high degree of genomic instability. In this chapter, we describe the different NMIBC subtype classification schemes reported. Finally, we discuss the clinical utility of molecular subtypes and what still needs to be answered before clinical implementation.

AB - Non-muscle-invasive bladder cancers (NMIBCs) show large variation in disease aggressiveness and treatment response which is not fully explained by differences in clinical and pathological factors. Researchers have therefore studied different molecular layers of tumors, mainly gene expression profiling, to unravel underlying molecular subtypes that can explain this phenotypic variation. In addition, molecular subtypes can potentially be used for risk stratification of patients and prediction of treatment response based on the biological tumor features. NMIBC subtypes have been investigated in combination with muscle-invasive bladder cancers (MIBCs), using NMIBCs only and separated by tumor stage. Molecularly high-risk tumors across schemes are generally characterized by pronounced cell cycle activity, frequent TP53 alterations and a high degree of genomic instability. In this chapter, we describe the different NMIBC subtype classification schemes reported. Finally, we discuss the clinical utility of molecular subtypes and what still needs to be answered before clinical implementation.

KW - Genomics

KW - NMIBC

KW - Proteomics

KW - Subtypes

KW - Transcriptomics

UR - http://www.scopus.com/inward/record.url?scp=105002925075&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-68505-7_13

DO - 10.1007/978-3-031-68505-7_13

M3 - Book chapter

AN - SCOPUS:105002925075

SN - 9783031685040

SP - 263

EP - 277

BT - Biology of Bladder Cancer

A2 - Knowles, Margaret A.

A2 - Dyrskjøt, Lars

PB - Springer Nature

ER -